Holen Sie sich die Stockscreener-App
100.30
2.36%
-2.42
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$102.72
Offen:
$102.71
24-Stunden-Volumen:
11.82M
Relative Volume:
1.05
Marktkapitalisierung:
$174.29B
Einnahmen:
$44.33B
Nettoeinkommen (Verlust:
$6.50B
KGV:
26.98
EPS:
3.717
Netto-Cashflow:
$7.40B
1W Leistung:
-2.50%
1M Leistung:
-9.27%
6M Leistung:
-24.34%
1J Leistung:
-19.44%
1-Tages-Spanne:
$99.34
$102.77
1-Wochen-Bereich:
$99.34
$103.83
52-Wochen-Spanne:
$99.34
$139.06
Abbott Laboratories Stock (ABT) Company Profile
Firmenname
Abbott Laboratories
Sektor
Branche
Telefon
(224) 667-6100
Adresse
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
100.30 | 178.49B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
339.15 | 129.89B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.21 | 112.87B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
61.79 | 91.07B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
77.87 | 45.63B | 6.07B | 1.06B | 1.34B | 1.8063 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Eingeleitet | The Benchmark Company | Buy |
| 2025-07-18 | Hochstufung | Jefferies | Hold → Buy |
| 2025-06-16 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-10-08 | Eingeleitet | Oppenheimer | Outperform |
| 2024-09-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Herabstufung | Edward Jones | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-21 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Bestätigt | Barclays | Overweight |
| 2023-04-20 | Bestätigt | Bernstein | Outperform |
| 2023-04-20 | Bestätigt | JP Morgan | Overweight |
| 2023-04-20 | Bestätigt | Raymond James | Outperform |
| 2023-04-20 | Bestätigt | UBS | Buy |
| 2023-04-20 | Bestätigt | Wolfe Research | Underperform |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-10-26 | Eingeleitet | Mizuho | Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-27 | Bestätigt | Credit Suisse | Outperform |
| 2022-01-27 | Bestätigt | Morgan Stanley | Overweight |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | UBS | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-27 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-01-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-06-01 | Herabstufung | Goldman | Neutral → Sell |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-02-07 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-11-30 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-01-30 | Bestätigt | Citigroup | Neutral |
| 2018-01-25 | Bestätigt | Stifel | Buy |
| 2018-01-25 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-19 | Bestätigt | Stifel | Buy |
Alle ansehen
Abbott Laboratories Aktie (ABT) Neueste Nachrichten
Jury awards total of $70 million in damages in case against Abbott over infant formula - The Guam Daily Post
Jury orders Abbott to pay US$70mil in preterm infant formula trial - Free Malaysia Today
Abbott Laboratories to pay $70M in damages in infant formula lawsuit - Chicago Sun-Times
Is Abbott Laboratories (ABT) Appealing After Recent Share Price Pullback? - Yahoo Finance
Chicago jury awards millions to families after babies fall ill after consuming Abbott Laboratories formula - ABC7 Chicago
Jury orders Abbott to pay $70 million in preterm infant formula trial, company says - Reuters
Cook County jury awards total of $70 million in damages in cases against Abbott over infant formula - Chicago Tribune
Abbott Jury Awards at Least $53 Million in Infant-Formula Trial - Bloomberg.com
Abbott (ABT) Ordered to Pay $17M in Baby Formula Case - GuruFocus
Abbott Ordered to Pay $53 Million in NEC Baby Formula Trial as Punitive Damages Loom - Consumer Notice
Abbott Laboratories stock (US0028241000): Is diagnostics strength enough to counter nutrition pressu - AD HOC NEWS
Abbott Laboratories Stock (ABT) Moved Down by 3.04% on Apr 10: A Full Analysis - TradingKey
-3.05% for Abbott Laboratories stock as persistent selling outweighs support - Traders Union
Abbott Laboratories stock hits 52-week low at $100.85 By Investing.com - Investing.com South Africa
Abbott Laboratories stock hits 52-week low at $100.85 - Investing.com
Abbott Laboratories price faces negative outlookForecast today10-04-2026 - Economies.com
Abbott survey finds ‘information overload, confusion and cost’ affecting health choices in US - Fierce Pharma
Dividend Roundup: AGNC Investments, Abbott Labs, AbbVie, and more (AGNC:NASDAQ) - Seeking Alpha
Abbott Laboratories: Solid Q1 Setup and Resilient MedTech/Diagnostics Support Path to 2026 Targets Amid Manageable Geopolitical Headwinds - TipRanks
How Abbott Baby Formula Verdict and Rising Litigation Risk May Reshape Abbott Laboratories' (ABT) Investment Profile - simplywall.st
Abbott Laboratories (ABT) Ordered to Pay $53M Over Infant Formul - GuruFocus
Chicago jury orders Abbott to pay $53M in preterm infant formula trial - Seeking Alpha
Abbott jury awards at least US$53 mil in infant-formula trial - The Edge Singapore
Jury orders Abbott to pay US$53 mil in pre-term infant formula trial, says Chicago Tribune - The Edge Malaysia
Abbott jury awards at least $53 million in infant-formula trial - MSN
Jury orders Abbott to pay $53 million in preterm infant formula trial, media report says - Yahoo! Finance Canada
Abbott Laboratories must pay at least $53 million in cases over infant formula, jury decides - The Daily Gazette
Could Buying This Dividend Pharma Stock Today Set You Up for Life? - The Motley Fool
Abbott Hit With $53M Verdict Over Baby Formula Harms - Law360
How The Abbott Laboratories (ABT) Investment Story Is Shifting With New Targets And Trial Updates - Yahoo Finance
Goldman Sachs Lowers Price Target for Abbott Laboratories (ABT) Today | ABT Stock News - GuruFocus
Abbott India Ltd stock: Why it's drawing global investor attention now - AD HOC NEWS
Abbott Laboratories (ABT) likely to benefit from nutrition segment recovery - MSN
Abbott (ABT) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Abbott Laboratories: A Dividend Aristocrat With A Compelling Valuation And Return Potential - Seeking Alpha
DNA Sequencing Market Leading Players AnalysisAbbott - openPR.com
Rep. Richard McCormick Buys Abbott Laboratories Stock - National Today
Jury Deliberating in Cook County Case Over Abbott Laboratories' Formula for Premature Babies - National Today
Jury Deliberates in Case Over Abbott Formula for Preemies - National Today
Assessing Abbott Laboratories (ABT) Valuation After Precision Oncology Integration With Flatiron Health - simplywall.st
Jury deliberating in Cook County case over Abbott Laboratories’ formula for premature babies - Chicago Tribune
Abbott (ABT) Rises Yet Lags Behind Market: Some Facts Worth Knowing - Yahoo Finance
Abbott Urges Ill. Jury To Reject Claims Formula Led To NEC - Law360
Abbott Laboratories stock rises Wednesday, still underperforms market - MarketWatch
Exocrine Pancreatic Insufficiency Market: Expanding Revenue Landscape to 2034 – DelveInsight | First Wave BioPharma, Abbott Products, AAIPharma, Solvay Pharmaceuticals, Abbott, Forest Laboratories - Barchart
A dividend king on sale: Is Abbott Labs a healthcare bargain? - MSN
Richard Dean Dr McCormick trades in various stocks, including Microsoft and Abbott Laboratories - Investing.com India
Barclays Adjusts Price Target on Abbott Laboratories to $144 From $142, Maintains Overweight Rating - marketscreener.com
Goldman Sachs Adjusts Price Target on Abbott Laboratories to $121 From $140, Maintains Buy Rating - marketscreener.com
Bacterial Vaginosis Market Is Going to Boom | Abbott Laboratories • Quidel Corporation • Hologic - openPR.com
Citi Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $136 - 富途牛牛
Finanzdaten der Abbott Laboratories-Aktie (ABT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
0.80%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):